NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

UPDATE 3-Australia's Healius snubs $1.21 bln bid from China's Jangho, says bid undervalues

Published 07/01/2019, 03:11 pm
© Reuters.  UPDATE 3-Australia's Healius snubs $1.21 bln bid from China's Jangho, says bid undervalues
HLS
-
601886
-
HSO
-

* Australian target takes four days to reject $1.2 bln approach

* Healius shares fall, but still above previous level (Adds Jangho comment, updates shares)

By Byron Kaye

SYDNEY, Jan 7 (Reuters) - Australian medical centre operator Healius Ltd HLS.AX on Monday rejected a A$1.7 billion ($1.21 billion) buyout approach from China's Jangho Group Co Ltd 601886.SS , denting its shares but leaving investors hoping for a higher offer.

The second-largest employer of Australian physicians took four days to reject the proposal from its major shareholder to buy the shares it did not already own, saying the approach was "opportunistic and fundamentally undervalues Healius." shares of Healius, formerly known as Primary Health Care, held above the price they were trading at before the Chinese construction materials company made its approach, a sign that investors remained hopeful of a more compelling bid.

The shares were down 6 percent at A$2.59 by late afternoon on Monday compared with Jangho's A$3.25 indicative offer price, but still higher than the A$2.25 last closing price before the Chinese firm made its approach.

"These sorts of things are always just opening gambits," said Morgans Stockbroking analyst Scott Power.

"If (Jangho) is serious they'll come back and keep pushing. It's early days in these takeover negotiations."

The Chinese company owns 16 percent of Healius, not enough to block a rival bidder, Power said.

Jangho in a statement said it was "disappointed that the Healius board has so promptly dismissed an offer that represents compelling value for Healius shareholders".

The proposal to buy Australia's second-biggest medical centre operator highlights the interest Chinese investors have in health-related companies, which are seen as high-quality assets with possible use back home, where an ageing population is straining existing services.

That interest has coincided with a difficult stretch for Australian health stocks which have been battered by concerns about tightening government subsidies and soft consumer spending. Hospital operator Healthscope Ltd HSO.AX is also fielding foreign takeover approaches following a decline in its share price. 2015, Beijing-headquartered Jangho paid $200 million for Australia's biggest eye care provider, Vision Eye Institute Ltd VEIXX.AX .

If Jangho did buy Healius, it would be one of the mainland's biggest healthcare plays in Australia. But it would need to clear the cross-border merger-and-acquisitions regulators of both countries. ($1 = 1.4063 Australian dollars)

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ China's Jangho makes $1.2 bln bid for Australian medical centre owner Healius

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.